Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2025-12-26 @ 1:41 AM
Study NCT ID:
NCT00417833
Status:
TERMINATED
Last Update Posted:
2024-06-03
First Post:
2007-01-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020256', 'term': 'Choroidal Neovascularization'}], 'ancestors': [{'id': 'D015862', 'term': 'Choroid Diseases'}, {'id': 'D014603', 'term': 'Uveal Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D009389', 'term': 'Neovascularization, Pathologic'}, {'id': 'D008679', 'term': 'Metaplasia'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'interventionModel': 'SINGLE_GROUP'}}, 'statusModule': {'whyStopped': 'Poor accrual', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2005-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-05', 'completionDateStruct': {'date': '2006-07'}, 'lastUpdateSubmitDate': '2024-05-31', 'studyFirstSubmitDate': '2007-01-03', 'studyFirstSubmitQcDate': '2007-01-03', 'lastUpdatePostDateStruct': {'date': '2024-06-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2007-01-04', 'type': 'ESTIMATED'}}, 'conditionsModule': {'conditions': ['Diabetic Proliferative Retinopathy', 'Vascular Vein Oclussion', 'Choroidal Neovascularization']}, 'descriptionModule': {'briefSummary': 'Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG).\n\nMethods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization\n* Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment\n* Completely studies\n\nExclusion Criteria:\n\nComplications\n\n* Tractional Detachment\n* Endophthalmitis'}, 'identificationModule': {'nctId': 'NCT00417833', 'briefTitle': 'Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment', 'organization': {'class': 'OTHER', 'fullName': 'Asociación para Evitar la Ceguera en México'}, 'orgStudyIdInfo': {'id': 'APEC-0017'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Intravitreal Bevacizumab', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Myrian L Hernández, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Asociación para Evitar la Ceguera en México'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Asociación para Evitar la Ceguera en México', 'class': 'OTHER'}}}}